590 related articles for article (PubMed ID: 25802138)
1. Neurocognitive functioning of subjects with putative pre-psychotic states and early psychosis.
Liu CC; Hua MS; Hwang TJ; Chiu CY; Liu CM; Hsieh MH; Chien YL; Lin YT; Hwu HG
Schizophr Res; 2015 May; 164(1-3):40-6. PubMed ID: 25802138
[TBL] [Abstract][Full Text] [Related]
2. Neurocognitive impairments in individuals at ultra-high risk for psychosis: Who will really convert?
Bang M; Kim KR; Song YY; Baek S; Lee E; An SK
Aust N Z J Psychiatry; 2015 May; 49(5):462-70. PubMed ID: 25425742
[TBL] [Abstract][Full Text] [Related]
3. General intellectual functioning as a buffer against theory-of-mind deficits in individuals at ultra-high risk for psychosis.
Hur JW; Byun MS; Shin NY; Shin YS; Kim SN; Jang JH; Kwon JS
Schizophr Res; 2013 Sep; 149(1-3):83-7. PubMed ID: 23810120
[TBL] [Abstract][Full Text] [Related]
4. Social cognition in clinical "at risk" for psychosis and first episode psychosis populations.
Thompson A; Papas A; Bartholomeusz C; Allott K; Amminger GP; Nelson B; Wood S; Yung A
Schizophr Res; 2012 Nov; 141(2-3):204-9. PubMed ID: 22959742
[TBL] [Abstract][Full Text] [Related]
5. Neurocognitive predictors of transition to psychosis: medium- to long-term findings from a sample at ultra-high risk for psychosis.
Lin A; Yung AR; Nelson B; Brewer WJ; Riley R; Simmons M; Pantelis C; Wood SJ
Psychol Med; 2013 Nov; 43(11):2349-60. PubMed ID: 23388122
[TBL] [Abstract][Full Text] [Related]
6. Neurocognitive predictors of functional outcome two to 13 years after identification as ultra-high risk for psychosis.
Lin A; Wood SJ; Nelson B; Brewer WJ; Spiliotacopoulos D; Bruxner A; Broussard C; Pantelis C; Yung AR
Schizophr Res; 2011 Oct; 132(1):1-7. PubMed ID: 21763109
[TBL] [Abstract][Full Text] [Related]
7. Salivary cortisol in early psychosis: New findings and meta-analysis.
Chaumette B; Kebir O; Mam-Lam-Fook C; Morvan Y; Bourgin J; Godsil BP; Plaze M; Gaillard R; Jay TM; Krebs MO
Psychoneuroendocrinology; 2016 Jan; 63():262-70. PubMed ID: 26520686
[TBL] [Abstract][Full Text] [Related]
8. Identifying neurocognitive markers for outcome prediction of global functioning in individuals with first-episode and ultra-high-risk for psychosis.
Sawada K; Kanehara A; Sakakibara E; Eguchi S; Tada M; Satomura Y; Suga M; Koike S; Kasai K
Psychiatry Clin Neurosci; 2017 May; 71(5):318-327. PubMed ID: 28294477
[TBL] [Abstract][Full Text] [Related]
9. No sex differences in neuropsychological performance in first episode psychosis patients.
Ayesa-Arriola R; Rodriguez-Sanchez JM; Gomez-Ruiz E; Roiz-Santiáñez R; Reeves LL; Crespo-Facorro B
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():149-54. PubMed ID: 24075821
[TBL] [Abstract][Full Text] [Related]
10. Neurocognitive function as a possible marker for remission from clinical high risk for psychosis.
Lee TY; Shin YS; Shin NY; Kim SN; Jang JH; Kang DH; Kwon JS
Schizophr Res; 2014 Mar; 153(1-3):48-53. PubMed ID: 24529365
[TBL] [Abstract][Full Text] [Related]
11. Impaired facial emotion recognition in individuals at ultra-high risk for psychosis and with first-episode schizophrenia, and their associations with neurocognitive deficits and self-reported schizotypy.
Lee SY; Bang M; Kim KR; Lee MK; Park JY; Song YY; Kang JI; Lee E; An SK
Schizophr Res; 2015 Jun; 165(1):60-5. PubMed ID: 25864951
[TBL] [Abstract][Full Text] [Related]
12. Cognitive functioning in at-risk mental states for psychosis and 2-year clinical outcome.
Simon AE; Grädel M; Cattapan-Ludewig K; Gruber K; Ballinari P; Roth B; Umbricht D
Schizophr Res; 2012 Dec; 142(1-3):108-15. PubMed ID: 23025995
[TBL] [Abstract][Full Text] [Related]
13. Working memory as a predictor of negative symptoms and functional outcome in first episode psychosis.
González-Ortega I; de Los Mozos V; Echeburúa E; Mezo M; Besga A; Ruiz de Azúa S; González-Pinto A; Gutierrez M; Zorrilla I; González-Pinto A
Psychiatry Res; 2013 Mar; 206(1):8-16. PubMed ID: 22985548
[TBL] [Abstract][Full Text] [Related]
14. Subjects at Ultra High Risk for psychosis have 'heterogeneous' intellectual functioning profile: a multiple-case study.
Magaud E; Morvan Y; Rampazzo A; Alexandre C; Willard D; Gaillard R; Kazes M; Krebs MO
Schizophr Res; 2014 Feb; 152(2-3):415-20. PubMed ID: 24365404
[TBL] [Abstract][Full Text] [Related]
15. Symptomatology and neuropsychological functioning in cannabis using subjects at ultra-high risk for developing psychosis and healthy controls.
Korver N; Nieman DH; Becker HE; van de Fliert JR; Dingemans PH; de Haan L; Spiering M; Schmitz N; Linszen DH
Aust N Z J Psychiatry; 2010 Mar; 44(3):230-6. PubMed ID: 20180725
[TBL] [Abstract][Full Text] [Related]
16. Baseline differences in clinical symptomatology between ultra high risk subjects with and without a transition to psychosis.
Velthorst E; Nieman DH; Becker HE; van de Fliert R; Dingemans PM; Klaassen R; de Haan L; van Amelsvoort T; Linszen DH
Schizophr Res; 2009 Apr; 109(1-3):60-5. PubMed ID: 19272756
[TBL] [Abstract][Full Text] [Related]
17. Social cognition and neurocognition as predictors of conversion to psychosis in individuals at ultra-high risk.
Kim HS; Shin NY; Jang JH; Kim E; Shim G; Park HY; Hong KS; Kwon JS
Schizophr Res; 2011 Aug; 130(1-3):170-5. PubMed ID: 21620681
[TBL] [Abstract][Full Text] [Related]
18. Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial.
Bolt LK; Amminger GP; Farhall J; McGorry PD; Nelson B; Markulev C; Yuen HP; Schäfer MR; Mossaheb N; Schlögelhofer M; Smesny S; Hickie IB; Berger GE; Chen EYH; de Haan L; Nieman DH; Nordentoft M; Riecher-Rössler A; Verma S; Thompson A; Yung AR; Allott KA
Schizophr Res; 2019 Apr; 206():67-74. PubMed ID: 30558978
[TBL] [Abstract][Full Text] [Related]
19. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
[TBL] [Abstract][Full Text] [Related]
20. Twelve-month psychosis-predictive value of the ultra-high risk criteria in children and adolescents.
Armando M; Pontillo M; De Crescenzo F; Mazzone L; Monducci E; Lo Cascio N; Santonastaso O; Pucciarini ML; Vicari S; Schimmelmann BG; Schultze-Lutter F
Schizophr Res; 2015 Dec; 169(1-3):186-192. PubMed ID: 26526751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
